Anton P. Porsteinsson, MD

The director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester discussed treatment response and safety findings from the phase 3 ACCORD study assessing AXS-05 for agitation in Alzheimer disease. [WATCH TIME: 6 minutes]

The director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester talked about recent results on the phase 3 ACCORD trial assessing AXS-05 for agitation in Alzheimer disease. [WATCH TIME: 8 minutes]

The director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester offered an extensive overview of 3 monoclonal antibodies in development for Alzheimer disease. [WATCH TIME: 9 minutes]

The Director of the University of Rochester Alzheimer's Disease Care, Research and Education Program discussed the ongoing study, which is exploring s-citalopram in patients with Alzheimer who also have symptoms of agitation.